个人简介

B. Pharmacy, GND University, India, 2000 M.S. Medicinal Chemistry, NIPER, India, 2001 Research Associate, Ranbaxy Labs Ltd. (now Daiichi Sankyo), 2002 JRF, National Institute of Immunology, 2003 PhD University of Arizona, 2008 Postdoctoral Associate, University of Illinois, 2010-2013 Assistant Professor of Chemistry, Virginia Tech, 2013-present

研究领域

Medicinal Chemistry & Chemical Biology

Cancer is a complex and multifactorial problem that we often seek to treat with one-dimensional solutions, not surprisingly with limited practical gain in overall patient survival. Work in my lab aims to harness the power of organic synthesis to develop materials and approaches that address the problem underlying current uni-targeted approaches – the rapid resistance emergence, the evasive cancer stem cells, and the brief period of positive clinical outcome for cancer patients. It is anticipated that vigorous efforts in this direction will illuminate many areas of chemical and life sciences, and may result in innovative platforms to target future therapies. Our approach is interdisciplinary, combining ligand design and synthesis, combinatorial chemistry and high-throughput screening with bioinformatics, structural, molecular and cell biology, with the ultimate goal of revealing new basic biological mechanisms and disease treatments.

近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Josan J.S., and Katzenellenbogen, J.A. Designer antiandrogens join the race against drug resistance. eLife, 2013, 2, e00692. Xu L., Josan J.S., Vagner J., Caplan M.R., Hruby V.J., Mash E.A., Lynch R.M., Morse D.L., and Gillies R.J. Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc. Natl. Acad. Sci. USA, 2012, 109, 21295-21300. Josan J.S., Handl H.L., Sankaranarayanan R., Xu L., Lynch R.M., Vagner J., Mash E.A., Hruby V.J., and Gillies R.J. Cell-specific targeting by heterobivalent ligands. Bioconjugate Chem., 2011, 22, 1270-1278. (Featured on Journal Cover - July 20, 2011) Barkey N.M., Tafreshi N.K., Josan J.S., DeSilva C.R., Sill K.N., Hruby V.J., Gillies R.J., Morse D.L., and Vagner J. Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. J. Med. Chem., 2011, 54, 8078-8084. (Highlighted in ScienceDaily - Nov 4, 2011) Josan J.S., DeSilva C.R., Yoo B., Lynch R.M., Pagel M.D., Vagner J., and Hruby V.J. Fluorescent and lanthanide labeling for ligand screens, assays, and imaging. In Drug Design & Discovery: Methods & Protocols (Methods in Molecular Biology), Humana Press NY, 2010, 716: 89-126. Josan J.S., Morse D.L., Xu L., Trissal M., Baggett B., Davis P., Vagner J., Gillies R.J., and Hruby V.J. Solid-phase synthetic strategy and bioevaluation of a labeled δ-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging. Org. Lett., 2009, 11, 2479-2482. Xu L., Vagner J., Josan J.S., Lynch R.M., Morse D.L., Baggett B., Han H., Mash E.A., Hruby V.J., and Gillies R.J. Enhanced targeting with heterobivalent ligands. Mol. Cancer Ther., 2009, 8, 2356-2365. Vagner J., Xu L., Handl H.L., Josan J.S., Morse D.L., Mash E.A., Gillies R.J., Hruby V.J. Heterobivalent ligands cross-link multiple cell-surface receptors: the human melanocortin-4 receptor and the δ-opioid receptor. Angew. Chem. Int. Ed., 2008, 47, 1685-1688. Josan J.S., Vagner J., Handl H.L., Sankaranarayanan R., Gillies R.J., and Hruby V.J. Solid-phase synthesis of heterobivalent ligands targeted to melanocortin and cholecystokinin receptors. Int. J. Pep. Res. & Ther., 2008, 14, 293-300. Handl H., Sankaranarayanan R., Josan J.S., Vagner J., Xu L., Morse D.L., Gillies R.J., Hruby V.J. Synthesis and evaluation of bivalent NDP-a-MSH(7)H(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconugate Chem., 2007, 18, 1101-1109.